Yingshe Zhao
YOU?
Author Swipe
View article: Osteoclast-independent osteocyte dendrite defects in mice bearing the osteogenesis imperfecta-causing Sp7 R342C mutation
Osteoclast-independent osteocyte dendrite defects in mice bearing the osteogenesis imperfecta-causing Sp7 R342C mutation Open
Osteogenesis imperfecta (OI) is a group of diseases caused by defects in type I collagen processing which result in skeletal fragility. While these disorders have been regarded as defects in osteoblast function, the role of matrix-embedded…
View article: Data from Tumor α<sub>v</sub>β<sub>3</sub> Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases
Data from Tumor α<sub>v</sub>β<sub>3</sub> Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases Open
In breast cancer bone metastasis, tumor cells stimulate osteoclast-mediated bone resorption, and bone-derived growth factors released from resorbed bone stimulate tumor growth. The αvβ3 integrin is an adhesion recepto…
View article: Supplementary Figure Legends 1-3 from Tumor α<sub>v</sub>β<sub>3</sub> Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases
Supplementary Figure Legends 1-3 from Tumor α<sub>v</sub>β<sub>3</sub> Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases Open
Supplementary Figure Legends 1-3 from Tumor αvβ3 Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases
View article: Supplementary Figures 1-3 from Tumor α<sub>v</sub>β<sub>3</sub> Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases
Supplementary Figures 1-3 from Tumor α<sub>v</sub>β<sub>3</sub> Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases Open
Supplementary Figures 1-3 from Tumor αvβ3 Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases
View article: Supplementary References for Figure 2 from A Loss-of-Function Polymorphism in the Propeptide Domain of the <i>LOX</i> Gene and Breast Cancer
Supplementary References for Figure 2 from A Loss-of-Function Polymorphism in the Propeptide Domain of the <i>LOX</i> Gene and Breast Cancer Open
Supplementary References for Figure 2 from A Loss-of-Function Polymorphism in the Propeptide Domain of the LOX Gene and Breast Cancer
View article: Supplementary References for Figure 2 from A Loss-of-Function Polymorphism in the Propeptide Domain of the <i>LOX</i> Gene and Breast Cancer
Supplementary References for Figure 2 from A Loss-of-Function Polymorphism in the Propeptide Domain of the <i>LOX</i> Gene and Breast Cancer Open
Supplementary References for Figure 2 from A Loss-of-Function Polymorphism in the Propeptide Domain of the LOX Gene and Breast Cancer
View article: Data from A Loss-of-Function Polymorphism in the Propeptide Domain of the <i>LOX</i> Gene and Breast Cancer
Data from A Loss-of-Function Polymorphism in the Propeptide Domain of the <i>LOX</i> Gene and Breast Cancer Open
The lysyl oxidase (LOX) gene reverted Ras transformation of NIH 3T3 fibroblasts and tumor formation by gastric cancer cells, which frequently carry mutant RAS genes. The secreted lysyl oxidase proenzyme is processed to…
View article: Supplementary Figure 2 from A Loss-of-Function Polymorphism in the Propeptide Domain of the <i>LOX</i> Gene and Breast Cancer
Supplementary Figure 2 from A Loss-of-Function Polymorphism in the Propeptide Domain of the <i>LOX</i> Gene and Breast Cancer Open
Supplementary Figure 2 from A Loss-of-Function Polymorphism in the Propeptide Domain of the LOX Gene and Breast Cancer
View article: Supplementary Figures 1-3 from Tumor α<sub>v</sub>β<sub>3</sub> Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases
Supplementary Figures 1-3 from Tumor α<sub>v</sub>β<sub>3</sub> Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases Open
Supplementary Figures 1-3 from Tumor αvβ3 Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases
View article: Data from A Loss-of-Function Polymorphism in the Propeptide Domain of the <i>LOX</i> Gene and Breast Cancer
Data from A Loss-of-Function Polymorphism in the Propeptide Domain of the <i>LOX</i> Gene and Breast Cancer Open
The lysyl oxidase (LOX) gene reverted Ras transformation of NIH 3T3 fibroblasts and tumor formation by gastric cancer cells, which frequently carry mutant RAS genes. The secreted lysyl oxidase proenzyme is processed to…
View article: Data from Tumor α<sub>v</sub>β<sub>3</sub> Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases
Data from Tumor α<sub>v</sub>β<sub>3</sub> Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases Open
In breast cancer bone metastasis, tumor cells stimulate osteoclast-mediated bone resorption, and bone-derived growth factors released from resorbed bone stimulate tumor growth. The αvβ3 integrin is an adhesion recepto…
View article: Supplementary Figure 1 from A Loss-of-Function Polymorphism in the Propeptide Domain of the <i>LOX</i> Gene and Breast Cancer
Supplementary Figure 1 from A Loss-of-Function Polymorphism in the Propeptide Domain of the <i>LOX</i> Gene and Breast Cancer Open
Supplementary Figure 1 from A Loss-of-Function Polymorphism in the Propeptide Domain of the LOX Gene and Breast Cancer
View article: Supplementary Figure 2 from A Loss-of-Function Polymorphism in the Propeptide Domain of the <i>LOX</i> Gene and Breast Cancer
Supplementary Figure 2 from A Loss-of-Function Polymorphism in the Propeptide Domain of the <i>LOX</i> Gene and Breast Cancer Open
Supplementary Figure 2 from A Loss-of-Function Polymorphism in the Propeptide Domain of the LOX Gene and Breast Cancer
View article: Supplementary Figure 1 from A Loss-of-Function Polymorphism in the Propeptide Domain of the <i>LOX</i> Gene and Breast Cancer
Supplementary Figure 1 from A Loss-of-Function Polymorphism in the Propeptide Domain of the <i>LOX</i> Gene and Breast Cancer Open
Supplementary Figure 1 from A Loss-of-Function Polymorphism in the Propeptide Domain of the LOX Gene and Breast Cancer
View article: Supplementary Figure Legends 1-3 from Tumor α<sub>v</sub>β<sub>3</sub> Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases
Supplementary Figure Legends 1-3 from Tumor α<sub>v</sub>β<sub>3</sub> Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases Open
Supplementary Figure Legends 1-3 from Tumor αvβ3 Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases
View article: Structure-based design of selective, orally available salt-inducible kinase inhibitors that stimulate bone formation in mice
Structure-based design of selective, orally available salt-inducible kinase inhibitors that stimulate bone formation in mice Open
Osteoporosis is a major public health problem. Currently, there are no orally available therapies that increase bone formation. Intermittent parathyroid hormone (PTH) stimulates bone formation through a signal transduction pathway that inv…